维奈克拉、硼替佐米和地塞米松治疗复发多发性骨髓瘤后因骨骼再矿化导致的严重低钙血症 - Suppr | 超能文献

Severe Hypocalcemia Due to Skeletal Remineralization After Venetoclax, Bortezomib, and Dexamethasone for Relapsed Multiple Myeloma.

作者信息

Inglezou Lydia, Tsekou Giolanta, Kotsianidis Ioannis, Spanoudakis Emmanouil, Liapis Konstantinos

出版信息

Ann Pharmacother. 2022 Sep;56(9):1076-1078. doi: 10.1177/10600280211062626. Epub 2022 Jan 3.

DOI:10.1177/10600280211062626

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Severe Hypocalcemia Due to Skeletal Remineralization After Venetoclax, Bortezomib, and Dexamethasone for Relapsed Multiple Myeloma.维奈克拉、硼替佐米和地塞米松治疗复发多发性骨髓瘤后因骨骼再矿化导致的严重低钙血症

Ann Pharmacother. 2022 Sep;56(9):1076-1078. doi: 10.1177/10600280211062626. Epub 2022 Jan 3.

2

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.硼替佐米和地塞米松联合维奈托克治疗复发/难治性多发性骨髓瘤显示出良好的疗效和可接受的安全性。

Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.

3

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.维奈托克或安慰剂联合硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者（BELLINI）：一项随机、双盲、多中心、3 期临床试验。

Lancet Oncol. 2020 Dec;21(12):1630-1642. doi: 10.1016/S1470-2045(20)30525-8. Epub 2020 Oct 29.

4

Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.低剂量维奈托克联合硼替佐米、达雷妥尤单抗和地塞米松治疗复发/难治性多发性骨髓瘤患者的单中心回顾性研究。

Ann Hematol. 2021 Aug;100(8):2061-2070. doi: 10.1007/s00277-021-04555-3. Epub 2021 May 14.

5

Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.卡非佐米、维奈克拉和地塞米松用于复发/难治性多发性骨髓瘤

Br J Haematol. 2020 May;189(3):e73-e76. doi: 10.1111/bjh.16483. Epub 2020 Feb 3.

6

Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.来那度胺联合卡非佐米和地塞米松治疗伴有 t(11,14)(q13;q32)的复发/难治性多发性骨髓瘤：两例病例报告及文献复习。

J Med Case Rep. 2020 Apr 23;14(1):54. doi: 10.1186/s13256-020-02376-y.

7

Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.维奈托克联合硼替佐米、地塞米松和达雷妥尤单抗治疗多发性骨髓瘤

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):e339-e343. doi: 10.1016/j.clml.2018.06.003. Epub 2018 Jun 18.

8

Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient.维奈托克联合卡非佐米、阿霉素和地塞米松可恢复一名原本治疗难治性多发性骨髓瘤患者的反应性。

Haematologica. 2020 Mar;105(3):e138-e140. doi: 10.3324/haematol.2019.232330. Epub 2019 Aug 29.

9

A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma.单中心 Venetoclax 治疗复发/难治性多发性骨髓瘤的回顾性队列分析。

Leuk Lymphoma. 2020 May;61(5):1211-1219. doi: 10.1080/10428194.2019.1709835. Epub 2020 Jan 11.

10

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.卡非佐米或硼替佐米治疗复发或难治性多发性骨髓瘤（ENDEAVOR）：一项开放标签、随机、3 期临床试验的中期总生存分析。

Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23.